Monitoring ADAMTS13 activity is essential to distinguish congenital from acquired thrombotic thrombocytopenic purpura, guide treatment decisions, and prevent relapses. This evidence concerns the gene ADAMTS13 and acquired thrombotic thrombocytopenic purpura.